FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington	, D.C.	20549	
------------	--------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average	burden									
hours per response: 0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MAYLEBEN TIMOTHY M					2. Issuer Name <b>and</b> Ticker or Trading Symbol Esperion Therapeutics, Inc. [ ESPR ]								k all app Direc	ctor 10% C		10% O				
(Last) C/O ESP	•	First) (I	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/11/2020								X	Officer (give title below)  President 8			Other (specify below) & CEO			
3891 RANCHERO DRIVE, SUITE 150																				
(Street)	RBOR I	<b>Л</b> І 4	8108		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ind Line) X	Form Form	idual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting					
(City)	(	State) (2	Zip)												Perso	on				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					Execution Date,			Transaction Disposed Of (D) (Instr. 3. Code (Instr. 5)			, 4 and Securi Benefi		ies cially Following	Form:	Direct Indirect	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount (A		or P	rice	Transa (Instr. 3	ction(s)			(Instr. 4)	
Common Stock 03/11/2				2020		P		2,500	I	A	\$43	11	111,998		D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercis Price of Derivative Security		if any	med on Date, Day/Year)		Transaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D) or Indirect (I) (Instr.		11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	er						

**Explanation of Responses:** 

/s/ Richard B. Bartram, by power of attorney

03/12/2020

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.